UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

The New England journal of medicine, 2013-07, Vol.369 (4), p.341-350

2013

Volltextzugriff (PDF)

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Alzheimer's & dementia, 2016-02, Vol.12 (2), p.110-120

2016

Volltextzugriff (PDF)

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

Alzheimer's & dementia, 2023-04, Vol.19 (4), p.1227-1233

2023

Volltextzugriff (PDF)

A novel cognitive disease progression model for clinical trials in autosomal‐dominant Alzheimer's disease

Statistics in medicine, 2018-09, Vol.37 (21), p.3047-3055

2018

Volltextzugriff (PDF)

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Annals of neurology, 2006-03, Vol.59 (3), p.490-498

2006

Volltextzugriff (PDF)

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings

Current medical research and opinion, 2014-10, Vol.30 (10), p.2021-2032

2014

Volltextzugriff (PDF)

Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study

Alzheimer's research & therapy, 2018-04, Vol.10 (1), p.36-36, Article 36

2018

Volltextzugriff (PDF)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

Alzheimer's & dementia : translational research & clinical interventions, 2015-09, Vol.1 (2), p.111-121

2015

Volltextzugriff (PDF)

Meta-analysis of EEG test performance shows wide variation among studies

Neurology, 2003-02, Vol.60 (4), p.564-570

2003

Volltextzugriff (PDF)

Use of CAM Results in Delay in Seeking Medical Advice for Breast Cancer

European journal of epidemiology, 2003-01, Vol.18 (8), p.817-822

2003

Volltextzugriff (PDF)

Baseline characteristics of INTERCEPT‐AD: A phase 1 trial with ACU193 targeting soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Topline results of INTERCEPT‐AD: A phase I trial of Aβ oligomer‐targeting ACU193 in early Alzheimer’s disease

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Recruitment strategies and tactics for INTERCEPT‐AD: A phase I trial of Aβ oligomer‐targeting ACU193 in early Alzheimer’s disease

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia

The American journal of psychiatry, 2010-02, Vol.167 (2), p.181-189

2010

Volltextzugriff (PDF)

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

Alzheimer's & dementia, 2012-07, Vol.8 (4), p.261-271

2012

Volltextzugriff (PDF)

Lamotrigine Therapy of Epilepsy in Tuberous Sclerosis

Epilepsia (Copenhagen), 2001-07, Vol.42 (7), p.935-940

2001

Volltextzugriff (PDF)

Natural cubic splines for the analysis of Alzheimer's clinical trials

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2023-05, Vol.22 (3), p.508-519

2023

Volltextzugriff (PDF)

Alternatives to MMRM for preclinical Alzheimer’s clinical trials: Clinical trial design and implementation

Alzheimer's & dementia, 2020-12, Vol.16 (S9)

2020

Volltextzugriff (PDF)

Alternatives to MMRM for preclinical Alzheimer’s clinical trials

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer’s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid

Alzheimer's & dementia, 2021-12, Vol.17 (S9), p.n/a

2021

Volltextzugriff (PDF)

The Institute on Methods and Protocols for Advancement of Clinical Trials for ADRD (IMPACT‐AD): An update after two years of conduct

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Volltextzugriff (PDF)

AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial): Clinical trial design and implementation

Alzheimer's & dementia, 2020-12, Vol.16 (S9)

2020

Volltextzugriff (PDF)

AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial)

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

P2‐007: Exposure‐Adjusted Analysis of Treatment‐Emergent Adverse Events from Expedition and Expedition2 Trials of Solanezumab for The Treatment of Alzheimer’s Disease

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_12), p.P610-P611

2016

Volltextzugriff (PDF)

Adverse events and dropouts in Alzheimer's disease studies: What can we learn?

Alzheimer's & dementia, 2015-01, Vol.11 (1), p.24-31

2015

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(108)
Dissertationen
(1)

Sprache

Englisch
(109)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(55)
Humans
(54)
Female
(43)
Male
(38)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Adolescent
(24)
Neurology
(23)
Adult
(21)
Middle Aged
(21)
Psychiatry
(21)
Neurosciences & Neurology
(20)
Pharmacology. Drug Treatments
(18)
Child
(17)
Psychology. Psychoanalysis. Psychiatry
(17)
Aged
(16)
Treatment Outcome
(16)
Alzheimer's Disease
(14)
Neuropharmacology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

A novel cognitive disease progression model for clinical trials in autosomal‐dominant Alzheimer's disease

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings

Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

Meta-analysis of EEG test performance shows wide variation among studies

Use of CAM Results in Delay in Seeking Medical Advice for Breast Cancer

Baseline characteristics of INTERCEPT‐AD: A phase 1 trial with ACU193 targeting soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease

Topline results of INTERCEPT‐AD: A phase I trial of Aβ oligomer‐targeting ACU193 in early Alzheimer’s disease

Recruitment strategies and tactics for INTERCEPT‐AD: A phase I trial of Aβ oligomer‐targeting ACU193 in early Alzheimer’s disease

Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

Lamotrigine Therapy of Epilepsy in Tuberous Sclerosis

Natural cubic splines for the analysis of Alzheimer's clinical trials

Alternatives to MMRM for preclinical Alzheimer’s clinical trials: Clinical trial design and implementation

Alternatives to MMRM for preclinical Alzheimer’s clinical trials

AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer’s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid

The Institute on Methods and Protocols for Advancement of Clinical Trials for ADRD (IMPACT‐AD): An update after two years of conduct

AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial): Clinical trial design and implementation

AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial)

P2‐007: Exposure‐Adjusted Analysis of Treatment‐Emergent Adverse Events from Expedition and Expedition2 Trials of Solanezumab for The Treatment of Alzheimer’s Disease

Adverse events and dropouts in Alzheimer's disease studies: What can we learn?

Suchergebnisse filtern